Summary of Purpose
Emerging studies have shown that statin treatment has pleiotropic non-cholesterol-dependent effects in the setting of ischemic stroke. Recombinant tissue plasminogen activator (rt-PA) is the only proven effective pharmaceutical treatment for hyper-acute management of ischemic stroke, in spite of the deleterious side-effects such as hemorrhagic transformation and reperfusion injury. These harmful impacts...Read More →
The following dates are available for this trial. Trial information last updated on 18 April 2016.
|1 Jan 2015||20 May 2015||1 Apr 2017||1 Jul 2017||1 Apr 2016||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Allocation: Randomized
- Masking: Open Label
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
- LUSHA TONG, M.D.